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Although there is a large data gap before a true
biologically based dose-response (BBDR)
model can be constructed for mouse liver
tumors, it is desirable to use the existing exten-
sive bioassay data on trichloroethylene (TCE)
and its two metabolites, dichloroacetic (DCA)
and trichloroacetic (TCA), to explore the rela-
tionship among these three compounds and to
evaluate its potential impacts on low-dose
extrapolation. Data available include a) mid-
to long-term DCA bioassays from different
investigators (1-5), with water concentrations
ranging from 0.05 to 5 mg/L (considered as
one dataset); b) mid- to long-term TCAbioas-
says from different investigators (1,3-5), with
water concentrations ranging from 0.05 to 5
mg/L (considered as one data set); c) two TCE
bioassays (6,7) with gavage doses ranging from
1,000 to 2,400 mg/kg/day; d) one TCE
inhalation bioassay (8) with air concentrations
ranging from 100 to 600 ppm; and e) an initi-
ation-promotion (IP) study (3) with ethylni-
trosourea (ENU) as initiator and TCE, DCA,
and TCA as promoters (considered as three
data sets). Data from all these studies include
incidence rates of carcinomas and average
number ofcarcinomas per animal. There is
also supplemental laboratory information such
as labeling index on normal hepatocytes, and
c-Jun-positive cells by DCA, as reported in the
mode ofaction paper by Bull (9). Given such
an extensive data set, it is desirable to use these
data to investigate the feasibility ofa biological
hypothesis and to investigate their implications
on low-dose extrapolation. In addition to
mouse liver tumors, TCE also induces other
tumors (e.g., lung and kidney) in rats.
However, the existing database is not sufficient
to develop BBDRmodels forsuch tumors.
Specific Objectives
On the basis ofbioassay data on TCE and its
metabolites (DCA and TCA), it is possible to
perform statistical analyses to investigate the
feasibility ofa biological hypothesis proposed
by researchers: TCE induces liver tumors
mainlyvia its metabolites, DCAand/or TCA.
Both metabolites (DCA and TCA) act
through the clonal expansion ofpreexisting
initiated cells.
Under this hypothesis, animals with a
higher background tumor incidence are
expected to be more susceptible to tumor
induction from TCE exposure, assuming that
higher background tumor incidence is due to
higher frequence ofspontaneously induced
initiated cells. Therefore, confirmation ofthis
hypothesis would have profound implications
on low-dose extrapolation. It should be
emphasized, however, that the conclusions
reached from our statistical investigations can
at most serve as tentative guidance for future
research to improve low-dose extrapolation;
mathematical analyses alone cannot replace
the need for actual laboratory investigations.
Our analyses focus on carcinomas in male
mice because these data are more complete in
male than in female mice. We recognize that
other plausible hypotheses about liver tumors
in mice can be postulated. For instance,
hypotheses about interrelationships among
preneoplastic and neoplastic lesions (foci,
hyperplastic nodules, adenomas, and carcino-
mas) may be postulated. However, it requires
more biological insight than presently avail-
able to support a particular hypothesis. It
should be emphasized that the purpose ofthis
paper is not to provide unit risk estimates; it
is to demonstrate how a biological assump-
tion could impact risk estimates at low doses
even ifthe exact shape ofthe dose-response
function is not known.
Preliminary Considerations
In this article, we focus on analysis of tumor
incidence data, using other information (i.e.,
labeling index [LI] ofc-Jun-positive cells, and
averaged numbers of tumors/animal) to
evaluate the reasonableness of statistically
estimated parameters related to mitotic rate of
initiated cells in the model. Since the LI for
c-Jun-positive cells is available only for an age
of about 45 weeks, it can only be used to
check the reasonableness ofstatistically esti-
mated parameters related to cell division rate
ofinitiated cells around comparable ages. Our
model allows the rate to vary over the animal's
lifespan in apiecewise constant manner.
As mentioned earlier, ifall lesions (e.g.,
foci, hyperplastic nodules, adenomas, and
carcinomas) are considered together, a model
of multiple-pathway carcinogenesis may be
more appropriate. This approach is not
adopted here because it would involve more
assumptions requiring more data, and thus
make any meaningful inference impossible.
However, these types ofdata are very useful
for constructing a BBDRmodel.
Because TCE may affect the growth of
neoplastic lesions, the model should include a
parameter reflecting such an effect.
Furthermore, the model should allow for
piecewise constant parameters because some
parameters (e.g., cell mitotic rate) are known
to be age dependent (10), and the data avail-
able have different exposure levels over time.
For instance, in the low-dose group of the
National Cancer Institute (NCI)TCE bioas-
say (6), animals were exposed to 1,000
mg/kg/day of TCE by gavage from age 5
weeks to 17 weeks, 1,200 mg/kg/day from
age 17 weeks to 83 weeks, and followed up to
age 95 weeks; in the high-dose group, expo-
sure was 2,000 mg/kg/day from age 5 weeks
to 17 weeks, 2,400 mg/kg/day from age 17
weeks to 83 weeks, and followed up to age 95
weeks. Under this experimental condition,
the dose-affected parameters would have dif-
ferent values over different subintervals, with
cutoff points at ages 5, 17, and 83 weeks.
Exact exposure pattern over ages is used in all
modelings considered in this report.
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Model Construction
Since DCA is a metabolite produced in the
liver after exposure to TCA, alogical approach
to determining the contribution ofDCA and
TCA toward tumor induction from TCE is
first to develop a dose-response model for
DCA based only on DCA bioassays. Once
DCA dose response is determined, the next
step is to determine the effect ofTCA. Since
TCA produces DCA as a metabolite, the
effect ofTCA can be determined once DCA
dose response is known. As discussed later,
this approach is feasible only when the
amount ofDCA in the liver can be estimated.
When DCA in blood is used as dosimetry,
more uncertainty is introduced in the risk
assessment process ofliver tumors, making it
more difficult to interpret modeling results.
In this report, we adopt the biological
framework (but not the deterministic formu-
lation) suggested by Cohen and Ellwein (10),
as well as the stochastic formulation by Chen
and Farland (11) and its extended version
(12). Three special features ofthis model are
a) the mitotic rate is explicitly incorporated in
the model, b) unlike most other two-stage
models, a single malignant cell may not nec-
essarily become a tumor, and c) the model
allows for piecewise constant parameters. As
in all two-stage models, the parameters can-
not be uniquely estimated using a statistical
optimization procedure (13).
An approach preferred by statisticians is to
reparametertize parameters. Although this
approach is statistically appropriate, it defeats
the main objective of our investigation;
namely, to evaluate the implication of the
resultant model on low-dose extrapolation. It
should be noted that it is important to keep
each parameter as originally defined because
the essential purpose ofBBDR modeling is to
study the behavior ofdose response at low
doses, and because the shape of the
dose-response function at low doses is a func-
tion ofthe shape ofeach individual exposure-
related parameter in a model (14). An
advantage ofkeeping all model parameters as
originally defined is that the impact ofa bio-
logical parameter can beeasilyinterpreted. For
instance, a compound can induce cell popula-
tion growth either by increasing cell birth rate
b (i.e., b is dose dependent), or by decreasing
cell death rate d (i.e., d is dose dependent). If
the two parameters b and dare reparameter-
ized as a single parameter r = bidh it would be
difficult to differentiate the biological implica-
tion described above. Therefore, a meaningful
question to ask now is: Is there a set (unique
or not) ofDCA- and TCA-related parameters
that could be used to predict dose-response
data in all different studies available? Our
approach is to seeksuch a set ofparameters by
maximizing the likelihood function (without
actually attaining the absolute maximum from
DCA (and TCA ifnecessary) bioassays by
computer simulations to be explained below.
To reduce the number ofparameters to be
estimated from bioassay data, NTP historical
background data are used to estimate back-
ground parameters in the model. Without
relying on the reparameterization method, an
ad hoc approach to obtain parameter estima-
tion is by a) obtaining a set ofparameters cor-
responding to near optimal level (near
maximum likelihood) and b) by alternately
treating some (one or two, depending on the
number ofunknown parameters to be esti-
mated) ofparameters as known constants and
then optimizing other parameters, with a goal
to maximize likelihood function. This process
can be repeated as many times as one desires.
This approach would eventually yield a set of
parameters that can then be used to predict
response in other data sets, recognizing that
the parameters may not be unique (in some
statistical sense). It is interesting to point out
that it is relatively easy to obtain the final
parameters for the DCA model as presented
in Table A-1 in the Appendix without going
through as many iterative processes as one
may expect; one reason may be that all those
theoretically different sets ofnear-optimal
parameters really make no practical difference
in terms ofpredictability ofotherdatasets.
Median areas under curve (AUC) ofDCA
and TCA in livers from the posterior distribu-
tion ofa Bayesian statistical analysis (15) are
used as dosimetrics in our dose-response
analyses. These dosimetrics are provided by
Bois (15), who has performed a Bayesian
statistical analysis ofthe parameters in physio-
logically basedpharmacokinetic (PBPK) mod-
els for TCE and its metabolites on the basis of
a PBPK model developed by Fisher et al.
(16), using Markov chain Monte Carlo simu-
lation. Another PBPK model by Clewell (17)
has not been adopted for modeling liver
tumors because it does not provide AUC in
liver for DCA and TCA; it provides only
AUC in blood. As discussed later, ifClewell's
PBPKmodel is used forcalculatingdosimetry,
the condusion about the role oftumor induc-
tion in TCE bioassays by DCA and TCA
could be different from that when Fisher's
model is used, andwith more uncertainty.
A dose-response model for DCA is con-
structed by pooling all available bioassays
(Table 1). Since TCA also induces formation
ofmetabolite DCA, there are two dosimetrics
(AUC-DCA and AUC-TCA) for the TCA
dose-response model. Using the DCA-related
parameters obtained previously from DCA
bioassays, the next step is to construct a
dose-response model for TCA on the basis of
pooled data from TCA bioassays. The origi-
nal plan was to use the dose-response models
constructed for DCA and TCA to evaluate
the dose-response relationships of other
studies. It turns out that DCA alone could
account for the carcinomas observed in all the
other bioassays: TCE, TCA, ENU-TCE,
ENU-TCA, and ENU-DCA. An attempt to
consider bothAUC-DCA andAUC-TCA in
the dose-response model ofTCA leads to an
Table 1. Goodness offitfor DCA-induced carcinomas in male mice.
Exposure Dose Duration Incidence rate Predicted tumor Source
(g/L) (mg/kg/day) (weeks) AUC-DCAa (95% CI)" incidence rate (ref.)
0.5 77 104 14.01 15/24 (0.63) 0.61 (1)
(0.43, 0.81)
0.05 7.6 75 1.38 3/21 (0.14) 0.16 (2)c
(003, 0.36)
0.5 77 75 14.01 1/18 (0.06) 0.33 (2)c
(0, 0.27)
3.5 350 60 63.66 8/12 (0.66) 0.59 (2)c
(0.30, 0.90)
5.0 486 60 88.40 25/30 (0.83) 0.73 (2)c
(0.51, 0.94)
5.0 61 88.40 21/26 (0.80) 0.76 (3)
(0.61, 0.93)
1 122 52 22.19 0/11 (0.0) 0.20 (4)
(0, 0.28)
2 213 52 38.74 5/24(0.21) 0.30 (4)
(0.01, 0.41)
2 213 37d 38.74 0/11 (0.0) 0.27 (4)
(0, 0.28)
1 122 104 22.19 9/13(0.69) 0.75 (5)
(0.46, 0.99)
3.5 350 104 63.66 33/33 (1.00) 0.99 (5)
(0.89, 1.00)
aAUC: Average daily area under curve of DCA in liver tissue. b95% confidence intervals are calculated from Rohif and Sokol (25). cTumor incidence data are taken directly from the original pathology report (26).¶xposed to DCA for 37 weeks and followed up to
52 weeks.
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unreasonable dose-response prediction of
other studies.
Modeling Results
As discussed previously, there are eight sets of
dose-response data including TCE and its
two metabolites, DCA and TCA, involving
conventional bioassays and IP design ofexper-
iments (Tables 1-4). Although attempts were
made to fit dose-response models on the basis
ofboth DCAandTCA, no meaningful results
could be obtained. That is, when we assumed
that both DCA and TCAwere responsible for
TCE-induced tumors, we failed to obtain a set
ofparameters that can also be used to predict
tumor response in other studies. We found
that amount ofDCA metabolite alone could
adequately predict tumor response ofTCA
and TCE under either a conventional bioassay
or IP study. Parameters for DCA-based dose
response are given in Table A-1 in the
Appendix. The goodness offit of the DCA
dose-response curve is given in Table 1. Since
data from DCA were used as a base for fitting
a dose-response model, it is not surprising to
see a good fit for a DCA model. What is sig-
nificant is that DCA alone can be used to pre-
dict tumor response in all other studies, as
shown in Tables 2-4.
Goodness ofFitforthe DCA
Dose-ResponseRelationship
Data from five DCA studies are pooled as a
data set (Table 1) to fit adose-response model
for DCA. These studies have two common
features: a) sample size for each studywas very
small, ranging from 11 to 33 mice; b) most
studies had a duration ofless than 75 weeks. A
group with 2 g/L ofDCA in drinking water,
from the study of Bull et al. (4), had the
shortest duration ofexposure at only 37 weeks
and was followed up to 52 weeks. Among 11
dose groups, only 1 predicted value for the
dosed group of0.5 g/L from DeAngelo et al.
(2) falls outside the 95% confidence interval
(CI). We note that this dose group has unusu-
allylowobserved incidencewhen compared to
a much lower dosed group of0.05 g/L; 14%
(3/21) oftumor incidence in the lower dosed
group (0.05 g/L) versus 6% (1/18) in the
higher dosed group (0.5 g/L).
PredictngTCATumor Response
onthe BasisofIts DCA-Metabolized
DoseAlone
TCA bioassays in Table 2 are a collection of
TCA studies from four investigators. As
shown in Table 2, the prediction ofTCA
studies by its DCA metabolite is surprisingly
good. The TCA prediction is accomplished
by using the metabolically generated DCA
from TCA, the TCA bioassay tumors, and
the model parameters obtained previously
from the DCA bioassay. Only one predicted
value from the 0.5 g/L group in Daniel et al.
(1) falls outside the 95% CI. Note, however,
that the observed tumor incidence of0.38 in
the 0.5 g/L group in the study of Daniel et
al. seems unusually large compared to an
incidence of 0.32 at a 10-fold higher con-
centration of 5.0 g/L in Bull et al. (4). For
these two particular data points, the model
appears to better predict the data from Bull
et al. (4) than from Daniel et al. (1).
PredictingTCETumor Response
ontheBasis ofItsDCA-Metabolized
DoseAlone
There are three TCE bioassays available:
gavage studies by NCI (6) and National
Toxicology Program (NTP) (7), and an
inhalation study by Bell et al. (8). For the
NCI study (6), animals in the low-dose
group were exposed to 1,000 mg/kg/day of
TCE by gavage from age S weeks to 17
weeks, 1,200 mg/kg/day from age 17 weeks
to 83 weeks, and followed up to age 95
weeks; animals in the high-dose group were
exposed to 2,000 mg/kg/day from age 5
weeks to 17 weeks, 2,400 mg/kg/day from
age 17 weeks to 83 weeks, and followed up to
age 95 weeks. For the NTP study (7), ani-
mals were exposed to 1,000 mg/kg/day of
TCE by gavage from age 5 weeks to 1 10
weeks. Animals (male mice) in the study of
Bell et al. (8) were exposed to TCE by inhala-
tion for 6 hr/day, 5 days/week, 104 weeks.
For both NCI and NTP studies in Table
3, observed values are Kaplan-Meier esti-
mated lifetime tumor incidence after adjust-
ing for intercurrent mortality. However, only
crude incidences are given for Bell's inhala-
tion study because the time-to-event data are
not available. Since crude incidence tends to
underestimate true tumor rate because of
intercurrent mortality, it is expected that pre-
dicted incidence is higher than the crude
incidence as given in Table 3. Because the
background incidences differ significantly
among studies, comparison of predicted
versus observed responses are made in terms
ofexcess incidence = P(t,d) -P(t,O), where t
is the age at end ofstudy. As discussed later,
the excess risk is not the best way to remove
Table2. Comparison of observed and predicted TCA-induced tumor response on the basis of its DCA metabolite alone.
Exposure Dose Duration Observed incidence rate Predicted Source
(g/L) (mg/kg/day) (weeks) AUC-DCAa (95% Cl) incidence rate (ref.)
0.05 7.6 60 0.70 2/9 (0.22) 0.11 1()b
(0.03, 0.47)
0.5 77 60 7.12 8/21 (0.38) 0.16 (1)b
(0.18, 0.61)
4.5 441 95 40.80 21/24 (0.87) 0.85 (1)"
10.68, 0.97)
4.5 441 104 40.80 8/11 (0.73) 0.73 (5)
(0.41, 0.94)
5.0 486 61 44.97 7/22 (0.32) 0.47 (3)
(0.10, 0.54)
1 122 52 11.29 2/11 (0.18) 0.14 (4)
(0.02, 0.51)
2 213 52 19.71 4/24(0.16) 0.19 (4)
0.05, 0.36
2 213 37 19.71 3/11 (0.27) 0.17 (4)
(0.06, 0.59)
'AUC: average daily area under curve of TCA in liver tissue. bThe number of animals used in Daniel et al. (1) is estimated; only per-
centages ofanimals with tumors were reported.
Table 3. Predicted tumor response in TCE bioassays on the basis of its metabolite DCAalone.
Observed excess tumor Predicted excess
Study(ref.) AUC-DCA incidence rate(95% Cl) tumor incidence rate
NCI, 1976(6)
1,000/1,200 mg/kg/day 66.45-67.53 0.61 (0.46, 0.75) 0.71
2,000/2,400 mg/kg/day 70.34-71.26 0.86 (0.72, 0.99) 0.73
NTP, 1990(7)
1,000 mg/kg/day 66.45 0.65(0.51, 0.78) 0.76
Bell etal., 1978 (8)
100 ppm 2.180 0.1a 0.12
300 ppm 6.214 0.13a 0.24
600 ppm 10.82 0.26a 0.36
&These are crude incidence without adjusting for intercurrent mortality and thus may seriously underestimate the true incidence. The
observed (predicted) excess risk for dose dis calculated as the difference of tumor incidence between the exposed groups and control
groups. The mortality-adjusted observed tumor incidence for the control groups (and 95% Cl) are, respectively, 0.08 (0, 0.21), 0.24
(0.12, 0.37); and 0.18(notavailable) for NCI (6), NTP(7), and Bell et al. (8).
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the effect of differential background rates.
Excess risk is used in Table 3 because it
shows more transparently what is being done
and because the difference is not as drastic as
when cross-species extrapolation is involved.
PredictingTumor Responses in an
Initiation-Promotion StudyBased on
the DCA-Metabolized DoseAlone
In the IP study (3) male mice 15 days ofage
were administered ENU as an initiator by
intraperitoneal (i.p.) injection of 2.5 or 10
g/g body weight. When animals were 4
weeks old, promoters (TCE, TCA, or DCA)
in drinking water were added, and continued
until 65 weeks ofage. The effect ofENU is
assumed to increase the initiation rate para-
meters during the day ofinjection and for 2
days afterward (i.e., during 15-17 days of
age). Although ENU may also have a
promotion and/or second mutation effect, it
seems reasonable to assume that a single
injection of ENU affects only initiation
because promotion usually requires longer
exposure, and it is not expected to have
much effect on the second mutation because
the injection occurs at a very early stage of
life. The predicted values in Table 4 were
calculated by adjusting the initiation rate
parameter upward over the 15- to 17-day
interval so that the predicted background
tumor incidence was comparable to the
observed incidence in the control groups, in
which only ENU (without active promoters)
was administered. All predicted values were
within 95% confidence intervals of the
observed incidence.
Evaluating the Model against
Supplemental Data
On the basis oftumor incidence data alone,
the modeling results suggest that DCA could
be responsible for most ofthe tumor (carci-
noma) response in TCE and TCA bioassays.
Table 4. Observed versus predicted tumor response in an initiation-promotion study of male mice on the basis of
DCAdose alone.a,b
Observed incidence rate Predicted
ENU (mg/g) Promoter Dose (mg/L) AUC-DCA (95% Cl) incidence rate
10 TCE 40 0.17 7/19(0.37) 0.39
(0.17, 0.58)
2.5 40 0.17 1/25 (0.04) 0.18
(0.01, 0.20)
2.F3 0.013 3/27(0.11) 0.18
(0.02, 0.29)
0 40 0.17 3/32 (0.09) 0.10
(0.02, 0.25)
2.5 DCA 5 88.40 25/32 (0.78) 0.77
(0.60, 0.91)
2.5 2 38.74 19/29(0.66) 0.48
(0.47, 0.82)
0 5 88.40 21/26 (0.81) 0.75
(0.62, 0.93)
10.0 TCA 5 44.97 15/28 (0.54) 0.66
(0.33, 0.73)
2.5 5 44.97 11/23(0.48) 0.53
(0.23, 0.72)
2.5 2 19.71 16/33(0.48) 0.34
(0.28, 0.69)
0 5 44.97 7/22 (0.32) 0.47
(0.14, 0.54)
"Observed data from Herren-Freund et al. (3). bEffect of ENU is assumed to increase initiation parameter during 15-17 days of age
such thatthe predicted and observed background tumor incidence rates arecomparable.
Table 5. Comparison of laboratory-based versus model-based estimations of cell division rate for initiated cells at
age of45weeks.
Laboratory-based Model-based cell division
Concentration Ll in cell division rate rate around the comparable
(g/L) c-Jun+ cellsa derived from Lib age when Ll was takenc
0.02 18 0.033 0.034
0.1 18 0.033 0.034
0.5 22 0.041 0.035
2 27 0.052 0.036
"Data adapted from Bull(91. Development of cell kinetic model for liver cancer induced by dichloroacetate. bCalculated by[log(l/(l +
LI/100)1/(2 x t) where t = 3 days, proposed by Moolgavkar and Luebeck (19). cCalculated by ax[yo + yl x log(l + AUC-DCA)] =
0.523[6.631 x10-2 + 1.026 x 10-3 xlogO( +AUC-OCA)l, with parameters taken from Table A-1.
There are two available data sets, labeling
indices and number ofcarcinomas/animal,
which were not used to reach this condusion.
Therefore, it is ofinterest to evaluate whether
these data are consistent with the DCA
dose-response model developed.
DataonLabelingIndices
Labeling indices on cells with c-Jun+ taken
from within altered foci and tumors (18) are
useful for checking reasonableness ofcell divi-
sion rates that are statistically estimated from
incidence data. Stauber and Bull (18) mea-
sured replication rates within hyperplastic
nodules and tumors in mice induced by 2 g/L
DCA for 38 weeks and then mice were trans-
ferred to the indicated concentration ofDCA
in drinking water for an additional 2 weeks.
Cell replication rates were measured by quan-
tifying BrdU incorporation into DNA of
dividing cells over a 3-daytime interval.
As shown in Table 5, the model-based
estimates ofcell division rate around age 45
weeks appear to be comparable to the labo-
ratory-based values, which are converted
from LI to cell division rates by using a for-
mula proposed by Moolgavkar and Luebeck
(19). Note that these formula-converted
rates are themselves subject to uncertainty
because the formula can only be considered
an approximation ofreality.
DataonNumberofCarcinomas
perAnimal
The numberoftumors per animal is very use-
ful data for constructing a biologically based
dose-response model. However, these data
cannot be used in modeling because the indi-
vidual animal data are not available; for each
dosed group, only average number oftumors
per animal is available. To use these data, we
summarized in Table 6 all available bioassays
that consist ofgroups ofanimals exposed to
both DCA and TCA at the same dose level
and duration, with a sample size of 20 or
more. Sample size is ofconcern here because
no formal statistical test will be done. Data
from DeAngelo et al. (2) and Daniel et al.
(1) are not included in the table because there
are no sample sizes provided in the TCA
bioassay in Daniel et al. (1). In order to con-
clude that DCA is responsible for most ofthe
tumor response in TCAbioassays, one should
observe greater averaged number of
tumors/liver in the DCA bioassays than in
the TCA bioassays under the same experi-
mental conditions. The numbers in Table 6
appear to support this expectation.
Role of DCA and TCA in TCE-
Induced Carcinomas
We have demonstrated that it is possible to
find a set of parameters that adequately
describes the tumor (carcinoma) response
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observed in DCA bioassays. Based on this
DCA dose-response model, it in turn is capa-
ble ofadequately predicting tumor response
observed in seven other datasets. This suggests
that DCA metabolites may be responsible for
most, ifnot all, TCE-induced carcinomas. It
should be noted, however, that this conclu-
sion is based on carcinomas alone, as well as
dosimetry calculated from Fisher's PBPK
model. TCA may also play an important role
in TCE-induced tumors ifother neoplastic
lesions (e.g., adenomas, hyperplastic nodules)
are considered. The conclusion may also
depend on the choice ofPBPKmodel.
Uncertaintyfrom Use ofDifferent
PBPKModels
There is a significant "numerical" difference
with respect to the ratio AUC-DCA/
(AUC-DCA + AUC-TCA) between
Clewell's and Fisher's PBPK models. On the
basis ofFisher's model, DCA (AUC-DCA in
liver) accounts for about 1% oftotal metabo-
lites (TCA and DCA combined) when TCE
or TCA is administered as a parent com-
pound. Conversely, ifthe Clewell model is
used, DCA (AUC-DCA in blood) accounts
for about 3% oftotal metabolites when TCE
is administered as a parent compound, and
about 0.1-10% oftotal metabolites, depend-
ing on administered dose level of TCA.
However, one should view these numerical
differences carefully by recognizing that two
very different dosimetries are involved here:
one is AUC in liver, another is AUC in
blood. The same amount of DCA in blood,
but that originated from different routes of
exposure (e.g., inhalation and oral), may
have very different implications in terms of
its effects on liver tumor induction.
It is of interest to determine whether a
different conclusion would be reached if
dosimetry (AUC in blood) is calculated by
the Clewell PBPK model. This question
appears to be more difflcult than it first
appears because AUC-DCA in blood may
have very different implications with respect
to induction ofliver tumors, depending on
whether DCA, TCA, or TCE is administered
as a parent compound. Since the liver is the
target tissue, it is reasonable to assume that
AUC-DCA in the liver has the same effect
on liver tumor induction regardless of the
route ofexposure, but the answer to the ques-
tion is not so straightforward when AUC-
DCA in blood is used as a dosimeter. With
this consideration in mind, a compromise for
dose-response analysis is to use AUC-TCA
as a biomarker to represent effect ofTCA
(which could include effects from both TCA
and TCA-induced DCA). That is, AUC-
DCA induced by TCA in the body is not
explicitly considered (but it is represented by
AUC-TCA) in dose-response modeling. We
recognize that the choice ofAUC-TCA as a
biomarker to represent the effect ofTCA and
TCA-induced DCA in blood may result in
overprediction ofrisk due to TCE exposure,
as part of DCA in blood may come from
TCA. However, the bias is expected to be
small because TCA-induced DCA accounts
for only a small proportion ofthe total dose
(AUC-TCA + AUC-DCA) on the basis of
the Clewell model, and because TCA is
responsible for more than 70% of tumor
response, as shown in Table 7. The analysis
performed in this section is more to provide
insight into the problem than to solve the
problem itself.
IfAUC in blood derived from Clewell's
PBPK model is used as a dosimeter, it is pos-
sible to find a set ofparameters from DCA
and TCA that are capable of predicting
tumor response in TCE oral bioassays (even
though the predicted value for the high-dose
group in the NCI study falls slightly below
the 95% CI), but overpredict the response in
the inhalation study (Table 7). One may
argue, however, that the inhalation study's
failure to predict could be explained by the
fact that the AUC of DCA and TCA in
blood after inhalation exposure to TCE dif-
fers (overestimated) from the AUC after gav-
age administration, which is the basis ofdata
used to construct dose-response models for
DCA and TCA (used to predict tumor
response in TCE bioassays). Ifthis argument
is accepted, one could conclude that both
TCA and DCA are responsible for TCE-
induced tumors, even though the overall pre-
diction result is not as good as the results
when Fisher's model was used. As can be seen
from Table 7, TCA appears to account for
more than 70% ofTCE-induced carcinomas.
Implications of Resultsfor Risk
Assessment
The conclusion that DCA (and possibly
TCA also) is responsible for TCE-induced
tumors by acting on spontaneously induced
initiated cells has a profound implication on
extrapolating risk from mice to humans. As
demonstrated in Table 8, the excess risk at a
given dose is more than 90-fold higher for a
group with higher tumor background rate
(0.23 for male mice) than for a group with
lower background rate (0.002 for humans).
To extrapolate risk to humans from
animal-based models, it is assumed that life-
time risk to humans can be calculated from
the lifetime risk of animals by adjusting
(reducing) the initiation parameter in the
animal model so that the background life-
time risk is reduced from 0.23 for male, mice
to 0.002 for humans. On the basis of the
Fisher model, AUC-TCA in liver is esti-
mated to be 3.8 x 10-3 when humans are
exposed to 1 g/L of TCE in water. The
model does not provide an estimate for
AUC-DCA. The lack ofDCA in the human
model is because there is no clear evidence of
its formation in humans. In the absence of
better data, one may assume that the ratio of
AUC-DCA/(AUC-DCA + AUC-TCA),
which is about 1% in mice, is identical with
that ofhumans. Under this assumption, we
see from Table 8 that the unit risk is reduced
from 2.486 x 10-6 to 2.447 x 10-8 if the
background tumor rate is reduced from 0.23
to 0.002, a 100-fold reduction ofexcess risk.
Table 6. Averaged number of carcinomas per liver in DCA and TCA bioassays with identical experimental conditions,
and with at least 20 animals in a group.
Exposure Duration AUC-DCA DCA studies TCA studies, Source
(mg/L) (weeks) AUC-DCA induced byTCA No. carcinomas/liver No. carcinomas/liver (ref.)
2 52 38.74 19.71 0.25 0.17 (4)
5 61 88.4 44.97 1.7 0.5 (3)
Table 7. Predicted tumor response in TCE bioassays when dosimeters derived from Clewell's PBPK model are used.
Observed excess tumor Predicted excess tumor incidence rate
Study incidence (95% Cl) TCA only DCA only TCA + DCAa
NCI, 1976 (6)
1,000/1,200 mg/kg/day 0.61 (0.46, 0.75) 0.52 0.07 0.66
2,000/2,400 mg/kg/day 0.86 (0.72, 0.99) 0.58 0.08 0.71
NTP, 1990 (7)
1,000 mg/kg/day 0.65 (0.51, 0.78) 0.6 0.13 0.67
Bell etal., 1978 (8)
100 ppm 0.1lb 0.52 0.10 0.62
300 ppm 0.13b 0.59 0.13 0.67
600 ppm 0.261 0.63 0.14 0.70
'Values in the last column, TCA + DCA, are calculated from the dose-response model with two dosimeters, TCA and DCA. These values
need not equal the sum of values under TCA and DCA because different portions of the dose-response curve are involved at the given
doses of DCA, TCA, and TCA + DCA. bThese are crude incidences without adjusting for intercurrent mortality, and thus may seriously
underestimate the true incidence. The excess risk for dose d is calculated as the difference of tumor incidences between exposed
groups and control groups. The mortality-adjusted observed tumor incidences for controls (and 95% Cl) are, respectively, 0.08 (0, 0.21),
0.24(0.12, 0.37), and 0.18(notavailable)for NCI (6), NTP(7), and Bell etal. (8).
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Table 8. Lifetime excess risk-effect of DCA on species
with different background tumor incidence rates.
AUC-DCA in Lifetime background tumorincidence rates
liver(mg-hr/L) 0.23 0.016 0.002
0.0000388 0.000002 0 0
0.0003871 0.0000245 0.000002 0
0.001935 0.000124 0.00001 0.000001
0.03871 0.002452 0.0001923 0.0000242
0.3817 0.02203 0.001749 0.00022
3.871 0.1517 0.01315 0.001663
5 0.1847 0.01641 0.002077
Research Needs
Biological Data
As demonstrated in this article, dosimetry
plays an important role in our conclusion.
Admittedly, the importance ofPBPK models
would be greatly reduced ifthe objective were
not to explore the relationship among TCE
and its two metabolites, DCA and TCA. If
the relationship among these three com-
pounds were known, anydose surrogate prob-
ably would do a reasonably good job of
dose-response modeling. Nevertheless, the
need to understand interaction between these
compounds (or anyother reactive metabolites)
and the host tissue is obvious. Even ifwe
accept a simple (yet significant for risk assess-
ment) hypothesis that DCA and TCA pro-
mote the clonal expansion ofinitiated cells,
there still would be a need to understand the
dose-response relationship ofthese two com-
pounds with respect to cell dynamics ofiniti-
ated cells at all dose levels. Conceivably, to
understand such a relationship would require
extensive laboratory research at a molecular
level, as discussed by Bull in this volume (9).
The importance ofknowing dose-response
relationships for cell dynamic parameters in a
dose-response model has been discussed by
Crump (14). Crump (14) has shown that, at
low doses, the shape oftumor dose-response
function is completely dependent on the
dose-response function ofdose-dependent
model parameters.
A potentially useful knowledge may be
gained ifthe relationship between different
preneoplastic and neoplastic lesions is under-
stood. Theseend points, which includevarious
types offoci, hyperplastic nodules, adenomas,
and carcinomas, suggest that different mecha-
nisms may induce liver tumors; some may be
compound dependent and some may be spon-
taneously induced. It is difficult to conceive
that these lesions are linearly related, meaning
that one is a prerequisite for the others in lin-
ear sequence. This problem suggests the need
to develop a more flexible modeling procedure
than thetwo-stage models nowused.
More FlexibleModelingPtocedures
To understand the need for new modeling
approaches, we have to discuss the short-
comings ofexisting approaches. Most existing
models ofcarcinogenesis and the approaches
used to develop them suffer from the follow-
ingshortcomings:
* Only tumor incidence data can be
adequately incorporated into the two-
stage model. For instance, there have been
attempts to use preneoplastic data such as
foci (or nodules) in the liver to estimate
rates ofinitiation and proliferation under
the assumption that cells in foci (or nod-
ules) are preneoplastic lesions. The prob-
lem with such an approach is that one
cannot confidently decide which cells in
foci or nodules represent the initiated cells
defined in a two-stage model, even
though it is reasonable to assume that foci
and nodules are preneoplastic lesions. The
dilemma ofchoosing either foci or nod-
ules, but not both, to represent initiated
cells in a two-stage model mandates the
development ofan alternative approach
for BBDRmodeling.
* In addition to the shortcoming above, the
most serious drawback of the existing
BBDR modeling approach is extreme dif-
ficulty in modifying the existing models
to adopt a biological hypothesis beyond
the framework ofa two-stage, single-path-
way model. For instance, in considering
the shortcoming above when both foci
and nodules are available, a natural ques-
tion to ask is, "Why not construct a
model with both foci and nodules as two
intermediate stages ofcarcinogenesis?" Or
even better, one could construct a sto-
chastic model ofcarcinogenesis including
both foci and nodules as two intermediate
steps, along with a statistical (or observa-
tional) model with foci and nodules as
observations. It is very difficult to accom-
plish even such a modest goal using the
approach currently used to develop the
two-stage models. However, this can be
easily accomplished by using the state-
space approach proposed in Tan and
Chen (20), in which two systems ofmod-
els are constructed: one consists ofa set of
stochastic differential equations consistent
with the underlying hypothetical mecha-
nism ofcarcinogenesis, and the other con-
sists of an observational model that
reflects both actual observations and the
underlying mechanism. It is interesting to
point out that this modeling approach is
conceptually similar to PBPK modeling,
except that PBPK modeling uses deter-
ministic differential equations, not sto-
chastic differential equations. Tan and
Chen (20) have proposed a statistical
approach and numerical algorithms for
efficiently estimating model parameters
under various scenarios ofdata that may
become available in the future.
The above discussions should serve as
motivations to develop more flexible biolog-
ically based dose-response models, which
should be computationally simple yet bio-
logically realistic.
Appendix: A Tumor
Growth Model
Brief Description of Model and
Its Parameters
Model ParametersandNotations
The following parameters are incorporated in
the dose-response model, including initiation
rate (juj), proliferation rate (yoc), conversion
rate (yv2), and probability oftumor progres-
sion (q). The death rate for the initiated cells
is implicitly defined by p = X1 - v2- a).
Some ofthese parameters are dose dependent.
d dose ofDCA, in terms ofAUC-DCA,
which mayvaryover time.
D dose ofTCA, in terms ofAUC-TCA,
which mayvaryover time.
,ul initiation rate (per cell per day), which
is assumed to be independentofdose.
V2 probability ofproducing a malignant
cell at the end of an initiated cell
(I-cell) lifetime. v2 is assumed to be lin-
early related to dose.
a probability that an I-cell divides into
two daughter cells at the end ofits life-
time. The parameter ais assumed to be
dose independent.
q probability that a single malignant cell
will develop into a malignant tumor.
The value q is assumed to be linearly
related to dose.
y l/yis the mean I-cell lifetime in days; a
cell's lifetime ends ifit goes into mitosis,
or with cell death. Note that if one
assumes that the probability for a cell to
enter into mitosis is about the same as
cell death, then the mean cell lifetime
can be conveniently interpreted as time
to mitosis (i.e., cell turnover time); thus,
shorter cell lifetime implies more fre-
quent cell division. This cell turnover
rate is assumed to be related to dose by
yd,D) = yo + yllog(l + d) + y21og(1 +
D), which maybe agedependent.
Mt): number of (normal) target cells in the
population at age t.
It should be noted that the assumption
that p, is independent ofdose is reasonable
because it is not known that DCA either initi-
ates or promotes proliferation ofcells in nor-
mal liver tissue. The tumorgrowth modelwith
piecewise constant parameters is from Tan and
Chen (12) and is an extension ofa stochastic
model developed by Chen and Farland (11).
This model has a biological motivation similar
to the two-stage model proposed byGreenfield
et al. (21), which has been used by Cohen and
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Ellwein (22) to analyze bladder tumors.
However, the two models differ from each
other with respect to their mathematical for-
mulations; the one adopted in this report is a
stochastic model, whereas the other is a deter-
ministic model thatdoes not allowforparame-
ter estimation because it does not have
complete mathematical expression.
Although its most general form will not
be used here because ofthe lack ofdata, it is
worthwhile to note that the stochastic model
ofChen and Farland (11) has two desirable
features: a) it allows for any cell growth dis-
tributions (e.g., Gompertz) rather than
being limited to the exponential distribution
as in other existing models, and b) it incor-
porates the birth and death of tumor cells
rather than assuming that a tumor is born
once a single tumor cell occurs, as in the
MVK model [proposed by Moolgavkar and
Venzon (23) and Moolgavkar and Knudson
(24)]. Therefore, ifinformation on cell life-
time distribution and the progression phase
oftumor development is available, a reason-
ably realistic model can be constructed.
For completeness of this article, a brief
description ofthe model used in this report
will be presented here. We assume that the
number ofnormal cells initiated by an agent
in any given interval (x, x + t) is a Poisson
random variable with expectation
JX+ ',l(y)N(y)dy. Letf(t) be the probability
Jensity function for the lifetime ofan initi-
ated cell (I-cell). Foran I-cell, at the end ofits
lifetime iteither divides (mitosis) ordies (pro-
grammed or nonprogrammed death). If it
enters into mitosis, it either divides into two
I-cells with probability a, or divides into one
I-cell and one malignant cell (M-cell) with
probability v2. Note that at the end ofa cell's
lifetime the probability for the cell to die is f.
= 1 - a- V2. Asimilar setup (i.e., to allowfor
any cell lifetime distribution) can be made for
an M-cell. However, wewill confine ourselves
to a simpler version assuming that an M-cell
lifetime follows an exponential distribution.
Thus, we can simply assume that an M-cell
follows a simple birth-death process; it can
either divide into two M-cells with a rate am
ordiewith a ratepm.
When parameters are constant over time
(ages), the hazard function is given by
h(t) =p1v2qJa(t-s)N(s)m(t -s)ds
0
where
m(t) =
(Y2 -YD)2exp[A(t)a(y2 -yJ]
((1 -Yi) +(Y2 -1)exp[A(t)a(y2 -Yj)])2
where Y1 <Y2 are two real roots of a/ _
(a + ,B + v2q)y + ,B = 0; a + ,B + V2 = 1,
TableA-1. Estimated parameters for DCA dose-response model.
Age in days
Parameters <35 35-365 365+
Background 2.446 x 10.8 4.415 x 10A 0
DCA 0 0 0
Background 7.463 x 10-7 7.463 x 1071 7.463 x 10-
DCA 5.324x 10O 5.324 x 10O 5.32 x 10O
a:
Background 0.523 0.523 0.523
DCA 0 0 0
q:
Background 6.694x 10-1 6.694 x 10-1 6.694x 10-1
DCA 3.740x 1i03 3.740x 103 3.740x 10-3
Age indays
<7 7-15 15-75 75-426 426+
y*:
Background 0 5.99x10-20 1.219x10-1 6.631 x10-2 2.041 x10-2
DCA 7.760 x 10-11 1.026 x 103 6.492 x 103
q = 1 - f3pamlam, A(t) =JIa(x)dx, where a(t) =
f(t)l[1 - F(t)] is the hazard function ofthe
cell lifetime, and F(t) is the cumulative func-
tion off(t). Two special cases ofinterest here
are a(t) = g, when the exponential distribu-
tion is assumed, and a(t) = exp(-yt), when
the Gompertz distribution is assumed.
When exponential distribution (i.e., a(t) =
yor A(t) = yt) and q = 1 are assumed, the
model is equivalent to the MVK model. A
special case that may be more appropriate
than the exponential distribution is when the
Gompertz distribution is assumed; i.e., A(t) =
[1 -exp(-yt)]/y.
For the model with time-dependent para-
meters, assume that the study begins at time
ti. Divide time scale (to, t] into ksubintervals
L.= (t -1, tj],j= 1,2,...k-1, and Lk= (tk-l, td,
where tk = t. The parameters that vary over
subintervals (t,.1, tj, i = 1,2,...,k are gply ax,
1 V2 N. and those parameters related to
/(t). Thehazardfunction isgivenby
h(t) =
Y-[PIiv2jqN f aj(tj-s)m,(t-s)ds]
k n1 mj(ti-ti-I
i=j+1
where
k
[I m1(t -tj)=1,whenj = k
i=j+1
and
m1(t) =
(Y2j -yij) exp[Aj(t)aj(y2j -y1J)]
(( -Yij)+(Y2j -1)exp[Aj(t)aj(y2j -y1J)
2
whereYlj<yj are two real roots ofao/ -(aj
+P.+ v2jqj)y+ fj= 0; aj+pj+V2= 1;q1= 1
- dmiiamjj j= 1,2,...,k. The formulation of
m is not exact for the case where a, v2 (and
thus ,Balso) are not independent oftime.
When exponential distribution [i.e., A4t)
= yj(t- tfYl)] and *= 1 are assumed, the
model is equivalent to the MVK model with
piecewise constant parameters. A special case
that may be more appropriate than the expo-
nential distribution is when the Gompertz
distribution is assumed, i.e., whenAj(t) = {1 -
exp[- Xy,(t- t. Iffily..
An alternative formulation that may be
more suitable for developing a computer pro-
gram is given in Tan and Chen (12) under
the assumption ofexponential cell lifetime
distribution and constant a and v2. The
tumor free distribution function, SX(t), can be
written as
S(t) =
exp{-
_[Aiy(tj-l.sj) + .Ai(ti-.Si)]}
wheresj= tjif]< kand s= tifj= k and
A.B(t11,sj)=
2NjH Vj
WI +ZI
{-(sj-t
l )j+ 2 )
log[1 + 1z (ewIyijsr(ti-)1)]},
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s( ti, l Sj) =
4Ni.uliv2j(r X-z)J
+ w , +(w, -zl)exp(wAi+l,jl(ti,,tjl))1
Wi +Zi +(W, 1 ZI)exp(-l _l j(ti,St__
Wi+z/ +(W, -zl)exp(wjAq(ti-1,sj))
where
w1= [(a+p+ v2q)2 -4af/212 and
z1= aX-fP-2q.
Aii(s,t) = yi(t- s) ifboth s and tare in the
same closed subinterval [ti.1, tj] and
At (S,t) =
'Yi(ti S) + i SY (tr tr-1)+rj(t tj_l1 r=i+l
ifsE Li, te L., with t1 < tj
Table A-1 gives estimated parameters for
the DCAdose-response model, which is used
to predict tumor response in other studies as
given in Tables 2-4 and 8. For ease ofpre-
sentation, the parameter gthat is related to
mitotic rateseparately under the table because
it has more time divisions. This time division
is based on the work ofCohen and Ellwein
(10), who observed that the mitotic rate in
mouse livervaries with age.
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